Mitochondria-Targeted Peptide Accelerates ATP Recovery and Reduces Ischemic Kidney Injury
Citations
[...]
475 citations
462 citations
437 citations
Cites background from "Mitochondria-Targeted Peptide Accel..."
...Accumulating evidence suggests that SS-31, a mitoprotective drug, can target the mitochondrial membrane to inhibit the permeability transition and is very effective in minimizing ischemic AKI and the development of interstitial fibrosis.(158,159) Treatment with SS-31 has been shown to block proinflammatory cytokine expression and ameliorate glomerulosclerosis and interstitial fibrosis....
[...]
397 citations
Cites background from "Mitochondria-Targeted Peptide Accel..."
...under conditions of oxidative stress such as IRI (72-74)....
[...]
377 citations
Cites background or result from "Mitochondria-Targeted Peptide Accel..."
...…interac on British Journal of Pharmacology (2014) 171 2029–2050 2035 effective dose in rodents is 0.1–0.5 mg kg−1 given subcutaneously (s.c.) or in the peritoneum (i.p.), and dose-dependent responses were observed between 0.1 and 5 mg kg−1 (Yang et al., 2009; Szeto et al., 2011)....
[...]
...Mitochondrial permeability transition led to sustained inhibition of mitochondrial respiration; with ATP levels down by more than 30% even 1 h after return of blood flow (Szeto et al., 2011)....
[...]
...This clinical study is also supported by other animal studies showing the effectiveness of Bendavia in preventing acute ischaemia kidney injury (Szeto et al., 2011; Birk et al., 2013b)....
[...]
...Mitochondrial permeability transition led to sustained inhibition of mitochondrial respiration; with ATP levels down by more than 30% even 1 h after return of blood flow (Szeto et al., 2011)....
[...]
References
2,131 citations
1,731 citations
1,525 citations
1,303 citations
1,257 citations